Author + information
- Received July 12, 2019
- Revision received September 16, 2019
- Accepted September 16, 2019
- Published online September 7, 2020.
- Ethan J. Rowin, MD∗ (, )
- Barry J. Maron, MD and
- Martin S. Maron, MD
- Hypertrophic Cardiomyopathy Center and Research Institute, Tufts Medical Center, Boston, Massachusetts
- ↵∗Address for correspondence:
Dr. Ethan J. Rowin, Hypertrophic Cardiomyopathy Institute, Tufts Medical Center, 800 Washington Street, Boston, Massachusetts 02111.
• HCM is a genetic heart disease with enormously diverse phenotypic expression.
• The multimodality, complementary imaging approach is necessary to characterize HCM morphology completely and has direct impact on future clinical course and treatment strategies.
• Contemporary imaging interwoven with current treatment strategies has resulted in substantially reduced mortality with extended longevity and good quality of life for the vast majority of patients with HCM.
Noninvasive contemporary imaging with echocardiography and cardiovascular magnetic resonance (CMR) provide comprehensive characterization of the hypertrophic cardiomyopathy (HCM) heart including precise definition of left ventricle (LV) wall thickness and reliable identification of morphologic abnormalities of the mitral valve, LV chamber, and myocardial tissue characterization with late gadolinium enhancement (LGE) (fibrosis). Imaging also contributes to identification of patients at risk for sudden death including novel high-risk features such as LV apical aneurysm and extensive LGE. Exercise (stress) echocardiography should be considered to demonstrate physiologic provocation of LV outflow gradients and to distinguish from patients with nonobstructive HCM. Multimodality imaging identifies patients who are optimal candidates for invasive septal reduction therapy and directs preoperative planning for extended myectomy and to optimize alcohol septal ablation. Contemporary imaging interwoven with current management strategies have resulted in a low HCM-related mortality rate.
- cardiovascular magnetic resonance
- heart failure
- hypertrophic cardiomyopathy
- sudden death
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Cardiovascular Imaging author instructions page.
- Received July 12, 2019.
- Revision received September 16, 2019.
- Accepted September 16, 2019.
- 2020 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.